Dr. Farago on the FDA Approval of Pembrolizumab for Lower PD-1 Cutoff NSCLC

Anna F. Farago, MD, PhD
Published: Thursday, Apr 11, 2019



Anna F. Farago, MD, PhD, assistant professor of medicine at Harvard Medical School, discusses the FDA approval of single-agent pembrolizumab for the frontline treatment of patients with stage III non–small cell lung cancer (NSCLC), who are ineligible for surgery or definitive chemoradiation, or metastatic NSCLC, with a PD-L1 expression (tumor proportion score) level of ≥1% and do not harbor EGFR or ALK aberrations.
SELECTED
LANGUAGE


Anna F. Farago, MD, PhD, assistant professor of medicine at Harvard Medical School, discusses the FDA approval of single-agent pembrolizumab for the frontline treatment of patients with stage III non–small cell lung cancer (NSCLC), who are ineligible for surgery or definitive chemoradiation, or metastatic NSCLC, with a PD-L1 expression (tumor proportion score) level of ≥1% and do not harbor EGFR or ALK aberrations.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual School of Nursing Oncology™Sep 28, 20191.5
Medical Crossfire®: Experts Weigh-In on Emerging Immune Checkpoint Inhibitors and Combination Strategies for Advanced NSCLCNov 30, 20191.5
Publication Bottom Border
Border Publication
x